Literature DB >> 34187410

Osteopontin isoform c promotes the survival of cisplatin-treated NSCLC cells involving NFATc2-mediated suppression on calcium-induced ROS levels.

Jing Huang1, Mu Hu2, Huan Niu1, Jing Wang1, Yang Si1, Shan Cheng3, Wei Ding4.   

Abstract

BACKGROUND: Tumor microenvironment (TME) critically contributed to the malignant progression of transformed cells and the chemical responses to chemotherapy reagents. Osteopontin (OPN) is a secretory onco-protein with several splicing isoforms, all of which were known to regulate tumor growth and able to alter cell-cell or cell-TME communication, however, the exact role and regulation of the OPN splicing isoforms was not well understood.
METHODS: In this study, the effects of conditioned medium from the culture of OPN splicing isoforms overexpressing cells on cell functions were evaluated. The methods of nuclear calcium reporter assays and subcellular distribution of nuclear factor of activated T cells c2 (NFATc2) assays were used to investigate the molecular mechanism underlining the roles of OPN splicing isoforms.
RESULTS: We found that the survival of NSCLC cells treated with cisplatin was increased by secretory OPNc in the condition medium, where reduction of apoptosis by OPNc was associated with the activation of cellular calcium signals and subsequent nuclear translocation of NFATc2.
CONCLUSIONS: The results revealed a mechanism of OPN and downstream signal for tumor cells to survive in chemo-stressed TME, which emphasized the importance of secretory proteins in alternative splicing isoforms. Our study not only demonstrated the importance of OPN neutralization for anti-tumor effects, but also implied that modulation in calcium/NFATc2/ROS axis could be a novel approach for improving the long-term outcome of NSCLC treatment.

Entities:  

Keywords:  NFATc2; Osteopontin; Reactive oxygen species; Splicing isoform; Tumor microenvironment

Year:  2021        PMID: 34187410     DOI: 10.1186/s12885-021-08495-z

Source DB:  PubMed          Journal:  BMC Cancer        ISSN: 1471-2407            Impact factor:   4.430


  33 in total

Review 1.  Phospholipase C-gamma: diverse roles in receptor-mediated calcium signaling.

Authors:  Randen L Patterson; Damian B van Rossum; Nikolas Nikolaidis; Donald L Gill; Solomon H Snyder
Journal:  Trends Biochem Sci       Date:  2005-11-02       Impact factor: 13.807

2.  Prognostic values of osteopontin-c, E-cadherin and β-catenin in breast cancer.

Authors:  Hui Pang; Hailing Lu; Hongtao Song; Qingwei Meng; Yanbin Zhao; Na Liu; Fei Lan; Ying Liu; Suhong Yan; Xiaoqun Dong; Li Cai
Journal:  Cancer Epidemiol       Date:  2013-09-05       Impact factor: 2.984

3.  Porphyromonas gingivalis lipopolysaccharide regulates interleukin (IL)-17 and IL-23 expression via SIRT1 modulation in human periodontal ligament cells.

Authors:  Yong-Duk Park; Young-Suk Kim; Yu-Mi Jung; Sang-Im Lee; Young-Man Lee; Jae-Beum Bang; Eun-Cheol Kim
Journal:  Cytokine       Date:  2012-06-08       Impact factor: 3.861

Review 4.  Systemic Therapy for Locally Advanced and Metastatic Non-Small Cell Lung Cancer: A Review.

Authors:  Kathryn C Arbour; Gregory J Riely
Journal:  JAMA       Date:  2019-08-27       Impact factor: 56.272

Review 5.  Human osteopontin splicing isoforms: known roles, potential clinical applications and activated signaling pathways.

Authors:  E R Gimba; T M Tilli
Journal:  Cancer Lett       Date:  2012-12-12       Impact factor: 8.679

Review 6.  Osteopontin as potential biomarker and therapeutic target in gastric and liver cancers.

Authors:  Dong-Xing Cao; Zhi-Jie Li; Xiao-Ou Jiang; Yick Liang Lum; Ester Khin; Nikki P Lee; Guo-Hao Wu; John M Luk
Journal:  World J Gastroenterol       Date:  2012-08-14       Impact factor: 5.742

7.  Nuclear osteopontin-c is a prognostic breast cancer marker.

Authors:  K Zduniak; P Ziolkowski; C Ahlin; A Agrawal; S Agrawal; C Blomqvist; M-L Fjällskog; G F Weber
Journal:  Br J Cancer       Date:  2015-01-27       Impact factor: 7.640

Review 8.  The role of osteopontin in the progression of solid organ tumour.

Authors:  Hailin Zhao; Qian Chen; Azeem Alam; Jiang Cui; Ka Chun Suen; Aurelie Pac Soo; Shiori Eguchi; Jianteng Gu; Daqing Ma
Journal:  Cell Death Dis       Date:  2018-03-02       Impact factor: 8.469

9.  Osteopontin promotes cancer cell drug resistance, invasion, and lactate production and is associated with poor outcome of patients with advanced non-small-cell lung cancer.

Authors:  Xiaoping Ouyang; Yumin Huang; Xing Jin; Wei Zhao; Tao Hu; Feng Wu; Jianan Huang
Journal:  Onco Targets Ther       Date:  2018-09-19       Impact factor: 4.147

10.  Enhanced osteopontin splicing regulated by RUNX2 is HDAC-dependent and induces invasive phenotypes in NSCLC cells.

Authors:  Jing Huang; Siyuan Chang; Yabin Lu; Jing Wang; Yang Si; Lijian Zhang; Shan Cheng; Wen G Jiang
Journal:  Cancer Cell Int       Date:  2019-11-21       Impact factor: 5.722

View more
  1 in total

1.  Periostin Augments Vascular Smooth Muscle Cell Calcification via β-Catenin Signaling.

Authors:  Ioana Alesutan; Laura A Henze; Beate Boehme; Trang T D Luong; Daniel Zickler; Burkert Pieske; Kai-Uwe Eckardt; Andreas Pasch; Jakob Voelkl
Journal:  Biomolecules       Date:  2022-08-21
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.